IO Biomarkers: Where Do We Stand In 2017?

Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.

Dr Jeffrey Weber
Dr. Jeffrey Weber presents a review of biomarkers

More from Immuno-oncology

More from Anticancer